Skip to main content

Fulcrum Therapeutics, Inc.

FULC
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001680581

In the last 90 days, Fulcrum Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 154 institutions reported holding it in 13F filings for Q2 2026, worth $291.3M in total; no superinvestor holds it.

Q2 2021 vs. Q1 2021

How the institutions holding Fulcrum Therapeutics, Inc. changed between Q1 2021 and Q2 2021.

All holders in Q2 2021All holders in Q1 2021

13F holders of FULC: Q1 2021 compared with Q2 2021
MeasureQ1 2021Q2 2021Change
Holders6867−1
Shares26.9M26.8M−114.5K (−0.4%)
Value$317.0M$280.8M−$36.2M (−11.4%)

New holders (10)

Institutions that held Fulcrum Therapeutics, Inc. at the end of Q2 2021 but not at the end of Q1 2021.

Institutions new to FULC in Q2 2021
InstitutionSharesValue% of portfolio
Citadel Advisors LLC410,525$4.30M0.00%
Perceptive Advisors LLC294,118$3.08M0.04%
Altium Capital Management LP213,533$2.24M0.52%
Jacobs Levy Equity Management, Inc13,789$145.0K0.00%
Jump Financial, LLC12,699$133.0K0.01%
ProShare Advisors LLC11,619$122.0K0.00%
Bank Julius Baer & Co. Ltd, Zurich8,492$89.0K0.00%
Nisa Investment Advisors, LLC5,050$53.0K0.00%
Federated Hermes, Inc.658$7.00K0.00%
Smith Asset Management Group LP520$5.00K0.00%

Sold out (11)

Institutions that held Fulcrum Therapeutics, Inc. at the end of Q1 2021 and filed for Q2 2021 without it.